Avaleht › Äge müeloidne leukeemia › Oregon
Äge müeloidne leukeemia kliinilised uuringud osariigis Oregon
27 uuringut haiguse Äge müeloidne leukeemia jaoks otsivad osalejaid osariigis Oregon.
Linnad osariigis Oregon
Ametlik uuringutekst (inglise keeles)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- ja veel 7
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
Vanused 40–75 · Kõik sood · Uuendatud 2. okt 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
VärbamineFaas 2
Vanused 18–59 · Kõik sood · Uuendatud 28. sept 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Care Clinic Westside, Portland
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT05564390Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 24. sept 2026 · NCT03874052Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
VärbamineFaas 2
Vanused 18–59 · Kõik sood · Uuendatud 22. sept 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
VärbamineFaas 3
6 Months – 21 Years · Kõik sood · Uuendatud 17. sept 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Oregon Health & Science University, Portland
VärbamineFaas 1/2
30 Days · Kõik sood · Uuendatud 16. sept 2026 · NCT04065399Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
- OHSU Knight Cancer Institute, Portland
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT06504459Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Oregon Health and Science University, Portland
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. sept 2026 · NCT03471260Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Portland OR-OHSU, Portland
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. sept 2026 · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
VärbamineFaas 1/2
Kuni 22 aastane · Kõik sood · Uuendatud 25. aug 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Doernbecher Children's Hospital, Portland
VärbamineFaas 3
29 Days – 21 Years · Kõik sood · Uuendatud 24. aug 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Willamette Valley Cancer Institute, Eugene
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 20. aug 2026 · NCT07007312Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
VärbamineFaas 3
Vanused 18–75 · Kõik sood · Uuendatud 17. juuli 2026 · NCT05429632Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. juuli 2026 · NCT04659616Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
VärbamineFaas 2
Vanused 18–65 · Kõik sood · Uuendatud 13. juuli 2026 · NCT07228273Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Oregon Health and Science University, Portland
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 7. juuli 2026 · NCT07216443Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
- OHSU Knight Cancer Institute, Portland
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 6. juuli 2026 · NCT07548983A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Oregon Health & Science University/Doernbecher Children's Hospital, Portland
VärbamineVaatlusuuring
Kõik vanused · Kõik sood · Uuendatud 6. juuli 2026 · NCT01351545Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. juuni 2026 · NCT06357182A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Oregon Health and Science University, Portland
- Oregon Oncology Specialists, Salem
VärbamineFaas 2/3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. apr 2026 · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Oncology Associates of Oregon, Eugene
VärbamineFaas 1/2
Vanused 12 ja vanemad · Kõik sood · Uuendatud 24. märts 2026 · NCT04988555A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Oregon Health & Science University, Portland
VärbamineFaas 2
Vanused 18–66 · Kõik sood · Uuendatud 17. märts 2026 · NCT06859424A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- OHSU, Portland
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 9. veebr 2026 · NCT06950034Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Oregon Health & Science University, Portland
VärbamineTerved vabatahtlikud oodatud
Vanused 18–120 · Kõik sood · Uuendatud 25. juuli 2025 · NCT05237258Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.